Recent Posts on This Topic | See All >
[Sourve: Oncology Nursing News] - Research conducted at The University of Arizona suggests that a drug may be able to change the function of hard-to-treat tumor cells so they will be more responsive to chemotherapy or radiation.
To gain greater response rates on melanoma tumors in cell cultures, Randy Burd, PhD, assistant professor of nutritional sciences and member of The University of Arizona's BIO5 Institute, has been testing dacarbazine, the standard chemotherapeutic drug, along with its analog temozolomide, in combination with various bioactive compounds.
For more information: Tumor-Sensitizing Drugs May Enhance Cancer Therapy
Now available: “Action and Impact," a 2014 report on the grant programs and activities of the Flinn Foundation in Arizona biosciences, civic leadership, arts and culture, and the Flinn Scholars program.